ARTICLE | Company News
Hisamitsu, ANI Pharmaceuticals deal
July 21, 2014 7:00 AM UTC
ANI acquired from Hisamitsu’s Noven Therapeutics LLC subsidiary the NDA for Lithobid, an extended-release formulation of lithium carbonate for bipolar disorder, for an upfront cash payment of $11 mil...